CytomX Therapeutics Inc. (NASDAQ:CTMX) Director Ix L.P. Canaan sold 51,581 shares of the stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $11.50, for a total value of $593,181.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Ix L.P. Canaan also recently made the following trade(s):

  • On Monday, November 14th, Ix L.P. Canaan sold 86,270 shares of CytomX Therapeutics stock. The stock was sold at an average price of $11.16, for a total value of $962,773.20.
  • On Wednesday, November 9th, Ix L.P. Canaan sold 13,730 shares of CytomX Therapeutics stock. The stock was sold at an average price of $11.03, for a total value of $151,441.90.

Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) traded up 2.21% on Thursday, reaching $11.54. The company had a trading volume of 44,798 shares. CytomX Therapeutics Inc. has a 1-year low of $9.10 and a 1-year high of $24.68. The stock has a market capitalization of $420.08 billion and a P/E ratio of 0.49. The company’s 50 day moving average price is $12.88 and its 200-day moving average price is $11.72.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Separately, Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 11th.

Hedge funds and other institutional investors have recently modified their holdings of the company. Franklin Resources Inc. boosted its position in shares of CytomX Therapeutics by 11.2% in the second quarter. Franklin Resources Inc. now owns 333,500 shares of the company’s stock valued at $3,407,000 after buying an additional 33,500 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in CytomX Therapeutics by 186.0% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 165,624 shares of the company’s stock valued at $1,692,000 after buying an additional 107,706 shares during the last quarter. BlackRock Fund Advisors raised its stake in CytomX Therapeutics by 168.6% in the second quarter. BlackRock Fund Advisors now owns 527,248 shares of the company’s stock valued at $5,386,000 after buying an additional 330,966 shares during the last quarter. BlackRock Investment Management LLC raised its stake in CytomX Therapeutics by 179.6% in the second quarter. BlackRock Investment Management LLC now owns 76,710 shares of the company’s stock valued at $784,000 after buying an additional 49,279 shares during the last quarter. Finally, BlackRock Advisors LLC raised its stake in CytomX Therapeutics by 21,170.0% in the second quarter. BlackRock Advisors LLC now owns 542,384 shares of the company’s stock valued at $5,541,000 after buying an additional 539,834 shares during the last quarter. Institutional investors and hedge funds own 51.59% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

5 Day Chart for NASDAQ:CTMX

Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.